Galenica confirms earnings guidance for 2018 despite weaker sales growth
Wednesday, 19 December 2018
EBIT and sales guidance 2018
As Galenica previously announced on the release of its 2018 half-year results, the additional and higher than originally announced price reduction measures for medications by the authorities are impacting on sales growth. Galenica therefore expects sales growth for 2018 to be below the 2% forecast. However, management of the Galenica Group is confident of achieving the announced EBIT growth. Consequently, the outlook regarding proposal of a dividend of at least at the same level as the prior year to the Annual General Meeting in 2019 is unchanged.
Other press releases
Early succession planning for the Head of Products & Brands Business sector
Friday, 21 September 2018Galenica Group half-year results 2018
Tuesday, 7 August 2018First Annual General Meeting of Galenica Ltd.
Wednesday, 9 May 2018
Contact
Contact
Galenica Ltd.
Investors
Untermattweg 8
3027 Bern
3027 Bern
Tel. +41 58 852 85 29
Fax +41 58 852 85 35